These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 14501009)
81. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Kim HD; Jin JJ; Maxwell JA; Fukuchi K Immunol Lett; 2007 Sep; 112(1):30-8. PubMed ID: 17686533 [TBL] [Abstract][Full Text] [Related]
82. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Nath A; Hall E; Tuzova M; Dobbs M; Jons M; Anderson C; Woodward J; Guo Z; Fu W; Kryscio R; Wekstein D; Smith C; Markesbery WR; Mattson MP Neuromolecular Med; 2003; 3(1):29-39. PubMed ID: 12665674 [TBL] [Abstract][Full Text] [Related]
83. Conformation-specific antibodies against multiple amyloid protofibril species from a single amyloid immunogen. Bonito-Oliva A; Schedin-Weiss S; Younesi SS; Tiiman A; Adura C; Paknejad N; Brendel M; Romin Y; Parchem RJ; Graff C; Vukojević V; Tjernberg LO; Terenius L; Winblad B; Sakmar TP; Graham WV J Cell Mol Med; 2019 Mar; 23(3):2103-2114. PubMed ID: 30663210 [TBL] [Abstract][Full Text] [Related]
84. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. Tucker S; Möller C; Tegerstedt K; Lord A; Laudon H; Sjödahl J; Söderberg L; Spens E; Sahlin C; Waara ER; Satlin A; Gellerfors P; Osswald G; Lannfelt L J Alzheimers Dis; 2015; 43(2):575-88. PubMed ID: 25096615 [TBL] [Abstract][Full Text] [Related]
85. Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42. Town T; Tan J; Sansone N; Obregon D; Klein T; Mullan M Neurosci Lett; 2001 Jul; 307(2):101-4. PubMed ID: 11427310 [TBL] [Abstract][Full Text] [Related]
86. Deglycosylation of anti-beta amyloid antibodies inhibits microglia activation in BV-2 cellular model. Rebe S; Solomon B Am J Alzheimers Dis Other Demen; 2005; 20(5):303-13. PubMed ID: 16273996 [TBL] [Abstract][Full Text] [Related]
88. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. Qing H; He G; Ly PT; Fox CJ; Staufenbiel M; Cai F; Zhang Z; Wei S; Sun X; Chen CH; Zhou W; Wang K; Song W J Exp Med; 2008 Nov; 205(12):2781-9. PubMed ID: 18955571 [TBL] [Abstract][Full Text] [Related]
89. An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice. Cheng YS; Chen ZT; Liao TY; Lin C; Shen HC; Wang YH; Chang CW; Liu RS; Chen RP; Tu PH EMBO Mol Med; 2017 May; 9(5):703-715. PubMed ID: 28356312 [TBL] [Abstract][Full Text] [Related]
90. Generation of auto-antibodies towards Alzheimer's disease vaccination. Frenkel D; Kariv N; Solomon B Vaccine; 2001 Mar; 19(17-19):2615-9. PubMed ID: 11257400 [TBL] [Abstract][Full Text] [Related]
91. Anti-Aβ Antibodies and Cerebral Amyloid Angiopathy Complications. Chantran Y; Capron J; Alamowitch S; Aucouturier P Front Immunol; 2019; 10():1534. PubMed ID: 31333665 [TBL] [Abstract][Full Text] [Related]
92. Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer's disease. Zurbriggen R; Amacker M; Kammer AR; Westerfeld N; Borghgraef P; Van Leuven F; Van der Auwera I; Wera S J Mol Neurosci; 2005; 27(2):157-66. PubMed ID: 16186626 [TBL] [Abstract][Full Text] [Related]
93. Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial. Kokjohn TA; Roher AE CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):88-97. PubMed ID: 19355930 [TBL] [Abstract][Full Text] [Related]
94. Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice. Crehan H; Liu B; Kleinschmidt M; Rahfeld JU; Le KX; Caldarone BJ; Frost JL; Hettmann T; Hutter-Paier B; O'Nuallain B; Park MA; DiCarli MF; Lues I; Schilling S; Lemere CA Alzheimers Res Ther; 2020 Jan; 12(1):12. PubMed ID: 31931873 [TBL] [Abstract][Full Text] [Related]
95. Immunodominant epitope and properties of pyroglutamate-modified Abeta-specific antibodies produced in rabbits. Acero G; Manoutcharian K; Vasilevko V; Munguia ME; Govezensky T; Coronas G; Luz-Madrigal A; Cribbs DH; Gevorkian G J Neuroimmunol; 2009 Aug; 213(1-2):39-46. PubMed ID: 19545911 [TBL] [Abstract][Full Text] [Related]
96. An in vitro paradigm to assess potential anti-Aβ antibodies for Alzheimer's disease. Jin M; O'Nuallain B; Hong W; Boyd J; Lagomarsino VN; O'Malley TT; Liu W; Vanderburg CR; Frosch MP; Young-Pearse T; Selkoe DJ; Walsh DM Nat Commun; 2018 Jul; 9(1):2676. PubMed ID: 29992960 [TBL] [Abstract][Full Text] [Related]
98. Efflux of human and mouse amyloid beta proteins 1-40 and 1-42 from brain: impairment in a mouse model of Alzheimer's disease. Banks WA; Robinson SM; Verma S; Morley JE Neuroscience; 2003; 121(2):487-92. PubMed ID: 14522007 [TBL] [Abstract][Full Text] [Related]
99. [Causal treatment of Alzheimer's disease: amyloid antibodies]. Pawlowski M; Warnecke T Inn Med (Heidelb); 2022 Sep; 63(9):1000-1008. PubMed ID: 35290498 [TBL] [Abstract][Full Text] [Related]